ArticleTissue engineering. Part A2019
M
Article in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.MedComm · 2026Review
- Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment.Biochemical Society transactions · 2025Review
- Harnessing mRNA for heart health: a new era in cardiovascular treatment.Theranostics · 2025Review
- IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism.Molecular therapy. Nucleic acids · 2023Article
- Modified mRNA as a Treatment for Myocardial Infarction.International journal of molecular sciences · 2023Review
- Modified mRNA Therapeutics for Heart Diseases.International journal of molecular sciences · 2022Review
- Anisotropic hydrogel fabricated by controlled diffusion as a bio-scaffold for the regeneration of cartilage injury.RSC advances · 2022Article
- Emerging nanotechnologies in cardiovascular medicine.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Mass Customized Outlook for Regenerative Heart Failure Care.International journal of molecular sciences · 2021Review
- Application of Modified mRNA in Somatic Reprogramming to Pluripotency and Directed Conversion of Cell Fate.International journal of molecular sciences · 2021Review
- Brachyury engineers cardiac repair competent stem cells.Stem cells translational medicine · 2021Article
- A preview of selected articles.Stem cells translational medicine · 2021Article
- Modified mRNA as a Therapeutic Tool for the Heart.Cardiovascular drugs and therapy · 2020Review
- Optimizing Modified mRNAMolecular therapy. Methods & clinical development · 2019Article
- mRNA-Based Protein Replacement Therapy for the Heart.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- Potential Application of Modified mRNA in Cardiac Regeneration.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
Abstract
impact statementThe M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.